On 15 MAY DARA Biosciences Inc (NASDAQ:DARA), an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments, announced its support for Neuropathy Awareness Week which is being observed and sponsored in the U.S. DARA Biosciences Inc (NASDAQ:DARA) weekly performance is 91.23%. On last trading day company shares ended up $2.18. Analysts mean target price for the company is $2.00. DARA Biosciences Inc (NASDAQ:DARA) distance from 50-day simple moving average (SMA50) is 1.91%.
On 13 MAY Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) reported Q1 EPS of ($0.25), $0.01 better than the analyst estimate of ($0.26). Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) shares advanced 5.48% in last trading session and ended the day on $3.27. CYCC return on assets is -97.10%. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) quarterly performance is -16.58%.
On 23 MAY Stemline Therapeutics Inc (NASDAQ:STML) announced its earnings results. The company reported ($0.70) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.72) by $0.02. Stemline Therapeutics Inc (NASDAQ:STML) shares moved up 4.79% in last trading session and was closed at $15.10, while trading in range of $13.84 – $15.24. Stemline Therapeutics Inc (NASDAQ:STML) year to date (YTD) performance is -22.96%.
On 8 MAY Agenus Inc (NASDAQ:AGEN) announced its financial results for the first quarter ended March 31, 2014.The company reported a net loss attributable to common stockholders of $409,000, or $0.01 per share, basic and diluted, for the first quarter of 2014, compared with a net loss attributable to common stockholders in the first quarter of 2013 of $8.8 million, or $0.35 per share, basic and diluted. In the first quarter of 2014, the company recorded other non-cash income of $9.9 million. Agenus Inc (NASDAQ:AGEN) ended the last trading day at $2.86. Company weekly volatility is calculated as 5.47% and price to cash ratio as 6.50. Agenus Inc (NASDAQ:AGEN) showed a positive weekly performance of 8.75%.
On 15 MAY VIVUS, Inc. (NASDAQ:VVUS) announced that a poster describing results of an analysis of the association between weight loss with Qsymia® (phentermine and topiramate extended-release) capsules CIV and annual concomitant medication costs will be presented at the AACE 23rd Annual Scientific & Clinical Congress at the Paris Las Vegas Hotel, Las Vegas, NV. VIVUS, Inc. (NASDAQ:VVUS) weekly performance is 7.59%. On last trading day company shares ended up $4.95. Analysts mean target price for the company is $7.33. VIVUS, Inc. (NASDAQ:VVUS) distance from 50-day simple moving average (SMA50) is -6.56%.
Leave a Reply